23 April 2020
Russia’s Vector State Research Center of Virology and Biotechnology has formed a preliminary group of volunteers aged between 18 and 60 for preclinical trials of vaccine against the novel coronavirus, researcher Natalya Dumchenko has said.
Vector Director General Rinat Maksyutov said in early April that preclinical tests will begin in early May and last until June 22. The vaccine has already been tested on animals.
‘We have formed a preliminary group of volunteers, aged between 18 and 60, with the verified ‘healthy’ status. In other words, we have healthy volunteers without chronic conditions,” Dumchenko said in an interview to the information center that monitors the novel coronavirus situation.
She said that the majority of those volunteers are Vector employees, who are involved in developing the vaccine and checking its quality.
“In the run-up to the vaccination – no earlier than one week before it – an additional health screening will be held to confirm the ‘healthy’ status and the absence of antibodies to the virus,” Dumchenko added.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russia has expanded the mandatory health insurance program for 2024-2026
29 March 2024
Russian scientists have developed new TB vaccines for both injection and nasal administration.
29 March 2024
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024